Crinetics Pharmaceuticals, Inc.
CRNX
$35.70
-$0.35-0.97%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -465.32M | -423.10M | -369.83M | -328.25M | -298.41M |
| Total Depreciation and Amortization | 3.89M | 3.68M | 3.44M | 3.24M | 2.79M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 78.66M | 74.46M | 69.99M | 64.04M | 58.02M |
| Change in Net Operating Assets | 4.84M | -6.94M | -7.59M | -4.82M | 7.41M |
| Cash from Operations | -377.92M | -351.89M | -304.00M | -265.79M | -230.19M |
| Capital Expenditure | -5.76M | -6.33M | -6.00M | -3.75M | -3.84M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 179.67M | -418.95M | -563.50M | -657.34M | -570.97M |
| Cash from Investing | 173.91M | -425.29M | -569.49M | -661.09M | -574.82M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 40.61M | 569.84M | 625.58M | 623.20M | 1.03B |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 967.00K | -527.00K | 2.32M | -14.98M |
| Cash from Financing | 40.61M | 570.81M | 625.05M | 625.52M | 1.01B |
| Foreign Exchange rate Adjustments | -106.00K | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -163.51M | -206.37M | -248.44M | -301.36M | 209.65M |